Earendil Labs Announces $2.56 Billion Strategic Collaboration with Sanofi to Advance Bispecific Antibodies for Autoimmune Diseases

Jan 05, 2026 20:04 CST Updated 20:04

Helixon

AI Technology New Drug Developer

Sanofi

Pharmaceutical Manufacturer

Opportunities to go global are here!

EU and US pharmaceutical companies are seeking CLDN1 ADC products (Claudin 1, not Claudin18.2) for female cancers (breast cancer, cervical cancer, ovarian cancer, uterine cancer, etc.). Priority is given to products in the IND-enabling, IND filing, or Phase I clinical trial stages. The desired products should have differentiated advantages, a long patent life, and no FTO issues/risks. Preference is given to acquiring overseas rights.
Interested companies are invited to contact immediately: PharmaTimes BD Team
BD@drugtimes.cn

Main Body: 548 Words

Estimated reading time: 2 minutes

January 5, 2026Earendil Labs(Helixon Overseas Company) announced a strategic partnership with Sanofi,Apply its discovery platform to multiple autoimmune and inflammatory disease programs. Sanofi will lead the development and global commercialization of bispecific drug candidates arising from the collaboration. The transaction is subject to customary closing conditions.

Screenshot source:prnewswire

According to the cooperation agreement, Earendil Labs will obtain$160 million in near-term upfront and early-stage project milestone payments,Total potential value (including upfront payment, development, and commercialization milestones) could reach up to 2.56 billion US dollars.And the highest proportionDouble-digit percentage sales dividend.

This collaboration is a follow-up toThe further deepening of the cooperation between the two parties in April last year.April 17, 2025Sanofi Introduces Two Bispecific Antibodies from HelixonHelixon's global exclusive rights to HXN-1002 (α4β7/TL1A) and HXN-1003 (TL1A/IL-23).

WorkIn return,Earendil Labs will receive an upfront payment of $125 million and is eligible for up to $1.72 billion in development and commercial milestone payments, including a near-term payment of $50 million, as well as tiered royalties on product sales ranging from the high single digits to low double digits.

Source of Screenshot:Earendil Labs Official Website

Earendil LabsHelixon's affiliated company, registered in Delaware in December 2024, as shown on the official website.Peng JianAs the founder and CEO of the company, Zhu Zhenping serves as the president and co-CEO.

HelixonHelixon is a Chinese company focused on high-throughput antibody optimization.Incubated by the Artificial Intelligence Industry Research Institute of Tsinghua University, Helixon was founded in October 2021 by Jian Peng, a world expert in computational biology.

June 2022,HelixonHelixon raised 500 million yuan in funding against the trend during the pandemic.Led by Five Source Capital, with participation from Gaorong Capital, Neumann Capital, and three angel round investors Xianghe.Capital, Hillhouse Ventures, and Qingzhi Capital followed up with investments.

In February 2023, Dr. Zhu Zhenping joined Helixon as a co-founder and assumed the roles of President and Co-CEO.He will be responsible for the R&D of Helixon's innovative drugs and the advancement of its product pipeline, strategy formulation and operations, and will promote the company's development in China and globally.

Reference: 1.https://www.prnewswire.com/news-releases/earendil-labs-announces-strategic-collaboration-with-sanofi-to-discover-bispecific-antibodies-for-autoimmune-diseases-302652305.html

Semaglutide Patent Valid! Novo Nordisk Wins, But…

2026-01-04

Former Chairman of Hengrui Appointed as President of Simcere!

2026-01-04

Over $1.2 Billion! China-Produced Tri-Specific Antibody Goes Global with AbbVie

2025-12-31

First in 40 Years! FDA Approves New Motion Sickness Drug

2025-12-31

Copyright Statement/Disclaimer
This is a compilation article.
This article is for information exchange only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by PharmaTimes, sourced from the WeChat public image library, taken from the company's official website or the internet, or used in accordance with the CC0 protocol. The copyrights belong to the respective owners, and PharmaTimes makes every effort to credit the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
ClickView more exciting content!